Park West Asset Management LLC acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 1,015,000 shares of the company's stock, valued at approximately $24,979,000. Elanco Animal Health accounts for about 1.7% of Park West Asset Management LLC's holdings, making the stock its 25th largest holding. Park West Asset Management LLC owned approximately 0.20% of Elanco Animal Health at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Elanco Animal Health in the second quarter worth $1,202,198,000. Primecap Management Co. CA acquired a new stake in Elanco Animal Health in the 2nd quarter worth about $1,118,402,000. The Manufacturers Life Insurance Company purchased a new position in Elanco Animal Health in the 2nd quarter valued at $205,636,000. UBS Group AG boosted its position in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company's stock worth $331,669,000 after acquiring an additional 5,961,457 shares during the last quarter. Finally, Sei Investments Co. increased its holdings in shares of Elanco Animal Health by 737.5% in the first quarter. Sei Investments Co. now owns 5,650,393 shares of the company's stock valued at $135,214,000 after purchasing an additional 4,975,721 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.
Insider Buying and Selling at Elanco Animal Health
In other news, Director Paul Herendeen acquired 10,000 shares of the business's stock in a transaction dated Friday, August 7th. The stock was acquired at an average price of $23.68 per share, with a total value of $236,800.00. Following the completion of the transaction, the director directly owned 111,687 shares in the company, valued at approximately $2,644,748.16. This represents a 9.83% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Lawrence Erik Kurzius purchased 40,000 shares of the business's stock in a transaction on Thursday, August 20th. The stock was acquired at an average price of $23.40 per share, with a total value of $936,000.00. Following the completion of the acquisition, the director directly owned 188,647 shares in the company, valued at $4,414,339.80. The trade was a 26.91% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders bought 63,198 shares of company stock valued at $1,473,109. Corporate insiders own 1.14% of the company's stock.
Elanco Animal Health Stock Performance
NYSE:ELAN opened at $25.09 on Thursday. Elanco Animal Health Incorporated has a 52-week low of $17.11 and a 52-week high of $27.98. The company has a market capitalization of $12.54 billion, a PE ratio of -61.20, a price-to-earnings-growth ratio of 1.50 and a beta of 1.67. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The stock has a fifty day simple moving average of $24.61 and a 200-day simple moving average of $24.01.
Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company's quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities research analysts expect that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
ELAN has been the topic of several recent analyst reports. KeyCorp boosted their target price on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. JPMorgan Chase & Co. boosted their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, May 7th. UBS Group increased their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Wall Street Zen lowered Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a report on Sunday, May 24th. Finally, Piper Sandler reissued an "overweight" rating on shares of Elanco Animal Health in a research note on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $29.09.
Get Our Latest Research Report on ELAN
About Elanco Animal Health
(
Free Report)
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Elanco Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.
While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
